Who pays for microgravity research and manufacturing today, and who might pay tomorrow?
The short answer. today, four groups: defence agencies buying re-entry tests, governments funding research (NASA, NIH, NSF, ESA, JAXA), pharmaceutical and biotech companies running R&D campaigns, and a few materials and photonics firms. Tomorrow, if products succeed, drug and device makers buying production steps, specialist fibre and crystal buyers, and station operators buying parts made in orbit. Most revenue in 2026 comes from the first two groups; the commercial case for stations and capsules depends on the third and fourth growing.
Demand map, 2026
| Buyer | What they buy | Platform | Scale (Setcoin reading) | Evidence |
|---|---|---|---|---|
| US defence (AFRL, Navy) | Hypersonic re-entry tests | Capsules | Several missions a year | Varda W-2, W-3, W-5 |
| NASA, NIH, NSF | Research | ISS, capsules | Hundreds of payloads a year | ISS National Lab: 115 in FY2025 |
| ESA, JAXA, national agencies | Research, capsule development | ISS, capsules | Dozens of experiments; contracts | ESA cargo and GSTP; JAXA Kibo |
| Large pharma | Formulation and structure R&D | ISS facilities, capsules | Occasional campaigns | Merck, Lilly, BMS |
| Biotech start-ups | Product development (retina films, biomaterials, organoids) | ISS, capsules, future stations | Few missions | LambdaVision, Helogen |
| Photonics firms | Fibre drawing | ISS | Small lots | Flawless Photonics |
| Semiconductor firms | Crystal growth demonstrations | ISS, free-flyers | Demonstrations | United Semiconductors, Space Forge |
Demand map, 2035 (base case)
| Buyer | What they might buy | Condition |
|---|---|---|
| Defence | More re-entry tests | Hypersonic programmes continue |
| Drug and device makers | Production steps for intermediates and implants | Regulatory precedent |
| Specialist fibre buyers | Premium mid-infrared fibre | Quality proven |
| Station operators | Printed parts and maintenance | Stations operating |
| Research agencies | Research on commercial platforms | Funding follows researchers |
Concentration of demand
| Feature | Implication |
|---|---|
| Few large buyers | Providers depend on defence and agencies |
| Many small R&D buyers | Shared missions needed (Chapter 60) |
| No production buyers yet | Revenue base fragile |
What would change this view
A first production contract from a drug or device maker would add a new buyer class. A cut in agency research budgets would shrink the largest research buyer group.